University of Groningen

Biochemical Characterization of MLH3 Missense Mutations Does Not Reveal an Apparent Role of MLH3 in Lynch Syndrome

Ou, Jianghua; Rasmussen, Merete; Westers, Helga; Andersen, Sofie D.; Jager, Paul O.; Kooi, Krista A.; Niessen, Renee C.; Eggen, Bart J. L.; Nielsen, Finn C.; Kleibeuker, Jan H.

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2009

[Link to publication in University of Groningen/UMCG research database](#)

Biochemical Characterization of *MLH3* Missense Mutations Does Not Reveal an Apparent Role of MLH3 in Lynch Syndrome

Jianghua Ou,[1] Merete Rasmussen,[2] Helga Westers,[1] Sofie D. Andersen,[2] Paul O. Jager,[1] Krista A. Kooi,[1] Renée C. Niessen,[1] Bart J. L. Eggen,[3] Finn C. Nielsen,[4] Jan H. Kleibeuker,[5] Rolf H. Sijmons,[1] Lene J. Rasmussen,[2] and Robert M. W. Hofstra[1]*

[1]Department of Genetics, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands

[2]Department of Science, Systems and Models, Roskilde University, Denmark

[3]Department of Developmental Genetics, Groningen Biomolecular Sciences and Biotechnology Institute, University of Groningen, Haren, The Netherlands

[4]Department of Clinical Biochemistry, University Hospital of Copenhagen, Denmark

[5]Department of Gastroenterology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands

So far 18 *MLH3* germline mutations/variants have been identified in familial colorectal cancer cases. Sixteen of these variants are amino acid substitutions of which the pathogenic nature is still unclear. These substitutions are known as unclassified variants or UVs. To clarify a possible role for eight of these *MLH3* UVs identified in suspected Lynch syndrome patients, we performed several biochemical tests. We determined the protein expression and stability, protein localization and interaction of the mutant MLH3 proteins with wildtype MLH1. All eight MLH3 UVs gave protein expression levels comparable with wildtype MLH3. Furthermore, the UV-containing proteins, in contrast to previous studies, were all localized normally in the nucleus and they interacted normally with wildtype MLH1. Our different biochemical assays yielded no evidence that the eight MLH3 UVs tested are the cause of hereditary colorectal cancer, including Lynch syndrome.   © 2009 Wiley-Liss, Inc.

INTRODUCTION

Mismatch repair (MMR) proteins form a highly conserved group of proteins that play a crucial role in correcting DNA mismatches that have escaped the proofreading activity of DNA polymerases. In the human MMR system the mismatch recognition component is fulfilled by a heterodimeric protein complex composed of two MutS homologous (MSH) proteins. The major MSH-heterodimer consists of MSH2 and MSH6 (MUTSα). This heterodimer is able to recognize and bind to base-base mismatches as well as to small insertion/deletion loops. A minor and partially redundant mismatch recognizing/binding heterodimer called MUTSβ consists of the MSH2 and MSH3 proteins. This protein complex recognizes and binds mainly to larger insertion/deletion loops (Chung and Rustgi, 2003). During the mismatch repair process, when MUTSα/MUTSβ recognize DNA mismatches that arise during DNA replication, the protein complex binds to the mismatch, thereby inducing a conformational change of the heterodimer and allowing ATP to bind and activate the protein complex. After activation of the MUTS complex, a heterodimer of two MutL homologous (MLH) proteins will bind to the DNA/protein complex. Two heterodimers composed of either MLH1 or PMS2 (MUTLα) or MLH1 and MLH3 (MUTLγ) are proven interactors with the MSH2-containing DNA-protein complex. These MLH complexes are thought to coordinate the downstream repair events, involving different proteins such as exonucleases (*e.g.*, EXO1) and DNA polymerases (Tishkoff et al., 1997; Tran et al., 2001; Liberti and Rasmussen, 2004). The heterodimer MLH1-PMS2 (MUTLα) interacts with both MUTSα and MUTSβ, whereas the heterodimer MLH1-MLH3 (MUTLγ) is believed to participate in insertion/deletion loop (IDL) repair

and to primarily function in conjunction with MSH2-MSH3 (Flores-Rozas and Kolodner, 1998; Harfe et al., 2000).

Chen et al. (2005), showed in mice that *Mlh3* deficiency causes microsatellite instability, impaired DNA damage response, and increased gastrointestinal tumor susceptibility. Results obtained in recent in vivo studies show that Mlh3 deficiency increases the mutation frequency of insertion-deletion loops. Furthermore, a primary role for the Mlh1-Mlh3 heterodimer in suppression of gastrointestinal tumor initiation in mice has been suggested (Chen et al., 2008). In addition, cultured mammalian cells, stably expressing a dominant negative truncated human MLH3, showed microsatellite instability (MSI) (Lipkin et al., 2000). In contrast, the effect of loss-of-function mutations in yeast indicates a minor role for the MLH3 yeast protein (Mlh3p) in MMR (Flores-Rozas and Kolodner, 1998; Harfe et al., 2000). For an excellent review on the MMR process in humans see (Jiricny, 2006).

Loss of MMR proteins results in the accumulation of unrepaired mutations. It is therefore not unexpected that mutations in these MMR genes are associated with tumor development. Germline mutations in four MMR genes, namely *MLH1*, *MSH2*, *PMS2*, and *MSH6*, have been identified in the majority of families with hereditary nonpolyposis colorectal cancer or Lynch syndrome (Peltomaki and Vasen, 2004). Many of the mutations identified result in premature termination of translation and thus in loss-of-function of the encoded mutated protein. This loss of MMR function results in unrepaired mutations in noncoding but also in coding sequences. It is mainly these coding sequence mutations that contribute to tumor development (Perucho, 1999).

Recently, we identified nine *MLH3* missense mutations and an *MLH3* frameshift mutation in patients suspected of having Lynch syndrome (Wu et al., 2001). The missense mutations will be called UVs throughout this article because it is not yet known whether these DNA variants contribute to disease development. Identifying these DNA variants, in combination with the identification of somatic *MLH3* mutations in three tumors of patients with these DNA variants (Wu et al., 2001), led us to hypothesize that, besides the four known MMR genes, *MLH3* might also play a role in Lynch syndrome development. This thought is further strengthened by other articles describing the association of germline *MLH3* mutations with esophageal, colorectal

and endometrial cancer susceptibility (Liu et al., 2006; Taylor et al., 2006; Kim et al., 2007). However, as all but two of the variations identified so far were UVs, the role of *MLH3* in the development of Lynch syndrome is still under debate. We biochemically tested eight identified *MLH3* UVs to see whether there is a possible role for *MLH3* in Lynch syndrome.

MATERIALS AND METHODS

Cell Lines

HEK293T cells, human embryonic kidney cells that lack *MLH1* and *MLH3* expression due to hypermethylation of the promoter regions of both genes (Cannavo et al., 2005), were grown in DMEM, supplemented with 10% fetal bovine serum, 1% penicillin-streptomycin and L-Glutamine (all from Invitrogen, Breda, the Netherlands). HeLa cells (ATCC CCL-2; a cervical carcinoma cell line) were grown in DMEM containing 10% FBS and 1% penicillin-streptomycin (all from Gibco, Taastrup, Denmark).

In Silico Analysis of the Unclassified Variants in MLH3

A description of the different *MLH3* UVs that were tested and the clinical characteristics of the mutation carriers are given in Table 1 and in Figure 1. Alignments with MLH3 homologous proteins from six other vertebrates were obtained by blasting the complete MLH3 protein to assess whether the variant amino acids had been evolutionarily conserved. The program used was M-Coffee (http://www.tcoffee.org) (Moretti et al., 2007). The following sequences were used in the Blast search: *Homo sapiens*, *Rattus norvegicus*, *Mus musculus*, *Canis familiaris*, *Bos taurus*, *Gallus gallus*, *Xenopus tropicalis*, *Pan troglodytes*, and *Saccharomyces cerevisiae*.

All eight *MLH3* UVs were further analyzed in silico for putative functional effects by determining the Grantham's chemical distance that considers composition, polarity and volume (Grantham, 1974) and by using the Align GVGD algorithm (Grantham variation and Grantham deviation), a web-based program that combines the biophysical characteristics of amino acid and protein multiple sequence alignments to predict where missense substitutions in genes of interest fall in a spectrum from enriched deleterious to enriched neutral (http://agvgd.iarc.fr/agvgd_input.php; Tavtigian et al., 2005; Mathe et al., 2006). We also evaluated the biochemical effects

TABLE I. Genetic and Clinical Data of the Tested *MLH3* UVs

Exon	Nucleotide change	Predicted protein change	Additional mutations in MSH2, MLH1 and/or MSH6	Somatic (second) MLH3 mutation	Cancer and age of diagnosis	MSI status[a]	Mononucleotide instability	Dinucleotide instability	Tetranucleotide instability	IHC MSH2/MLH1/MSH6
1	c.70C>G	p.Gln24Glu		Yes	CRC 50	H[2]	0/4 (0 %)	4/11 (36 %)	5/9 (56 %)	+/+/+
1	c.1496A>G	p.Asn499Ser		No	CRC 62	H[2]	0/4 (0 %)	9/11 (82 %)	7/9 (78 %)	+/+/+
					EC 63	H	2/4 (50 %)	10/12 (83 %)	6/9 (67 %)	ND
1	c.1870G>C	p.Glu624Gln		No	CRC 56	L	1/4 (25 %)	4/11 (45 %)	6/9 (67 %)	+/+/+
1	c.2449A>G	p.Ser817Gly	MSH6 IVS9+43 ins10 bp	No	EC 46	EC:L	0/4 (0 %)	2/12 (17 %)	1/7 (14 %)	+/+/−
					OV 46	OV:H	0/4 (0 %)	4/10 (40 %)	4/8 (50 %)	+/+/+
1	c.2578delA	p.N860IfsX13		No	CRC 43	L	1/4 (25 %)	3/10 (30 %)	3/9 (33 %)	+/+/+
1	c.2941G>A	p.Gly981Ser		No	CRC 24	L	0/4 (0 %)	4/10 (40 %)	5/8 (63 %)	+/+/+
1	c.3020A>G	p.Asn1007Ser		Yes	CRC 49	L	0/4 (0 %)	1/11 (9 %)	1/9 (11 %)	+/+/+
11	c.4180G>A	p.Ala1394Thr		Yes	CRC 44	L[b]	0/4 (0 %)	4/12 (33 %)	5/9 (56 %)	+/+/+
12	c.4351G>A[c]	p.Glu1451Lys	MSH6 c.2633T>C	No	CRC 45	L	0/4 (0 %)	4/12 (33 %)	1/9 (11 %)	+/+/+
12	c.4351G>A		MSH6 c.651dupT	No	CRC41	L	0/4 (0 %)	2/11 (18 %)	1/9 (11 %)	+/+/−[d]

None of the families fulfilled the Amsterdam II criteria; all families fulfilled the Bethesda guidelines.

CRC, colon cancer; EC, endometrial cancer; OV, ovarian cancer; H, MSI-H; L, MSI-L; ND, not determined.

[a]MSI status determined by the use of the five consensus markers.

[b]These patients have no PMS2 germline mutation.

[c]A recent study on a Korean population identified c.4351G>A as a SNP (Kim et al., 2007).

[d]Loss of MSH6 is due to the truncating mutation identified.

of the amino acid substitutions by the "Russel method" at EMBL (http://www.russell.embl-heidelberg.de/aas/; Betts and Russell, 2003). Additionally, we used the polymorphism phenotyping (PolyPhen) algorithm (http://genetics.bwh.harvard.edu/pph). PolyPhen is a web-based algorithm that predicts how an amino acid substitution could possibly affect the structure and function of a human protein using straightforward physical and comparative considerations. Calculations are based on amino acid homology and structure databases and three-dimensional structure databases. In silico analysis using the PolyPhen algorithm was done on the entire MLH3 protein sequence. Amino acid substitutions are reported as benign, possibly damaging or probably damaging. The variants were also assessed by using the "Sort Intolerant From Tolerant" (SIFT) algorithm by submitting aligned sequences at the SIFT server. SIFT uses sequence homology and the physical properties of amino acids to predict the effect of amino acid substitutions.

Three web-based algorithms were used to predict possible splice defects initiated by the UVs: Netgene2 (http://www.cbs.dtu.dk/services/NetGene2), Splicesitefinder (http://violin.genet.sickkids.on.ca/~ali/splicesitefinder.html), and Splicesite predict (http://www.fruitfly.org/seq_tools/splice.html). As input we gave a fragment containing the exon sequence plus 200 nucleotides upstream and 200 bp downstream of the exon. This was done for exons 1, 11, and 12 since the eight UVs tested lie within these exons.

We also ran ESEfinder (http://rulai.cshl.edu/cgi-bin/tools/ESE3/esefinder.cgi?process=home), a program that searches for sequences that act as binding sites for four members of the serine/arginine rich family of splicing enhancer proteins. Input sequences are screened for consensus binding sequences for the SR proteins CF2/ASF, SC35, SRp40, and SRp55. Regions with scores above a certain threshold value are predicted to act as SR protein binding sites, and thus function as ESEs (exonic splice enhancers). The wildtype (or UV-containing) *MLH3* cDNA sequence (AB 039667) was used as input. The program was run in an exon-by-exon manner.

MLH3 Vectors and *MLH3* Mutants

To clone the *MLH3* cDNA (wildtype) in pAS2 (a yeast two-hybrid vector containing a GAL4 DNA binding domain) and pACT2 (a yeast two-hybrid vector containing a GAL4 activation

Figure 1. Schematic representation of the *MLH3* exon map (upper panel) and the MLH3 protein and location of the tested MLH3 UVs, the known polymorphism (in italics), and the truncating mutation in the protein. The green parts in the exon map represent the noncoding regions of exon 1 and exon 13. The light blue parts of the protein represent the MLH1 interaction domains obtained from Kondo et al. (2001). [Color figure can be viewed in the online issue, which is available at www.interscience.wiley.com.]

domain), *MLH3* was first cloned into pBluescript. *MLH3* was PCR-amplified using primers containing the 5′ end and the 3′ end of the coding sequence coupled to a *Bam*HI (forward) and an *Eco*47III (reverse) restriction site. An extra AG was inserted between the *Bam*HI site and the first codon of *MLH3* (to get *MLH3* in the correct reading frame after subsequent subcloning into pACT2 and pAS2). After cloning this PCR-amplified *MLH3* in pBluescript, the insert was sequenced and subcloned in pACT2 and pAS2 using the *Bam*HI and *Eco*47III restriction sites. Mutations [i.e., the eight UVs mentioned in Table 1, one known polymorphic missense variant (p.Ser845Gly) and the identified frameshift mutation (see Table 1)] were introduced in these plasmids using the Stratagene QuickChange XL Mutagenesis Kit (La Jolla, CA). This was done according to the manufacturer's instructions. After mutagenesis the *MLH3* inserts were sequenced to confirm the mutation status of the plasmids.

Wildtype *MLH3* (from pBluescript-MLH3) was cloned directly, in-frame with YFP, into pEYFPC1 (Clontech Laboratories, Woerden, the Netherlands) and the constructed YFP-MLH3 vector was used for subcellular localization studies. Mutations [(i.e., the eight UVs mentioned in Table 1, one known polymorphic missense variant (p.Ser845Gly) and the truncating mutation we identified (see Table 1)] were introduced in WT-YFP-MLH3 using the Stratagene QuickChange XL Mutagenesis Kit (La Jolla, CA). This was done according to the manufacturer's instructions. After mutagenesis all inserts were verified by sequencing.

Protein Expression of MLH3 in the HEK293T Cell Line

HEK293-T cells were seeded in a 6-well plate 24 hr before transfection to ensure 60% confluence on the day of transfection. Four micrograms of YFP-MLH3 vector (WT or mutant) was transfected using 10 μl Lipofectamine 2000 (Invitrogen, Carlsbad, CA). WT-CFP-MLH1 and WT-YFP-MLH3 were used as positive controls. Transfected HEK293T cells were lysed 48 hr after transfection using a nondenaturing lysis buffer (20 mM Tris-HCl, pH 8, 135 mM NaCl, 1.5 mM MgCl$_2$, 1 mM EGTA, 1% Triton X-100, 10% glycerol, protease inhibitors). Protein concentration determinations were performed according to Bradford (1976) and 75 μg of the cell lysate was loaded and size separated on a 6% SDS-PAGE gel. After separation by SDS-PAGE, proteins were transferred to a nitrocellulose membrane (Bio-Rad, Veenendaal, the Netherlands). MLH3 was detected with specific antibodies (Santa Cruz Biotechnology, Santa Cruz, CA) or with anti-GFP (GeneTex, San Antonio, TX) and anti-mouse IgG HRP-conjugated secondary antibody (Pierce Biotechnology, Rockford). Beta-tubulin (a housekeeping protein) was used as an internal loading control and detected with an anti-beta-tubulin antibody (Sigma-Aldrich, St. Louis, MO) and anti-mouse IgG HRP-conjugated secondary antibody (Pierce Biotechnology, Rockford). Signal visualization was performed with the Supersignal West Dura Extended Duration Substrate kit (Pierce Biotechnology, Rockford).

Subcellular Localization of MLH3

On the day prior to transfection, 100,000 cells were seeded in small glass Petri dishes (20 mm in diameter). On the day of transfection, the media were refreshed. For transfection 1 μg of plasmid DNA (also 1 μg in total for the double transfection experiments) and 3 μl Fugene6 per Petri dish was used. Fugene6 (3 μl) was mixed with 50 μl optimem and incubated for 5 min at room temperature. DNA was added and mixed, and this mixture was incubated for 20 min after which it was added to the cells. The cells were then incubated for ∼24 hr. After incubation, the transiently expressed, fluorescently labeled proteins were visualized by confocal laser scanning microscopy (Zeiss LSM510, Carl Zeiss MicroImaging GmbH, Jena, Germany).

Yeast Two Hybrid Analysis

To investigate the ability of UV-containing MLH3 proteins to form MLH1-MLH3 heterodimers, yeast two-hybrid assays were performed essentially as described by Rasmussen et al., (2000). pAS2-MLH1 and pACT2-MLH3 were cotransformed into the *Saccharomyces cerevisiae* strain Y190. Transformants were selected on synthetic dextrose minimal medium (SD) lacking tryptophan, leucine and histine (SD/-Trp/-Leu/ -His). At least five colonies were streaked onto an SD/-Trp/-Leu/-His plate that was supplemented with 25 mM 3-amino-1,2,4-triazole(3-AT). Colonies were further tested on SD/-Trp/-Leu/-His/3-AT +40 μg/ml 5-bromo-4-chloro-3-indolyl-β-D-galactosidase (X-gal) plates. Blue colonies that can grow on these selection plates express GAL4-tagged proteins that are able to interact. Several attempts to introduce pACT2-MLH3 p.E1451K into Y190 failed. The reason for this is unknown. The two-hybrid vectors containing MLH3 or MLH1, in combination with the empty vectors, were used as negative controls.

RESULTS

In Silico Analysis of the Unclassified Variants in MLH3

The alignment depicted in Figure 2 shows that one of the eight UVs changed a reasonably well-conserved amino acid (p.Gly981Ser), whereas the other seven of the eight UVs changed highly conserved amino acids. The results of the other in silico analyses of the MLH3 UVs are presented in Table 2. The Grantham scores and the "Russel's prediction" show that all amino acid substitutions are not likely to interfere with the function of MLH3. Seven of the eight UVs were predicted to be benign based on PolyPhen. Only UV, p.Asn499Ser, was predicted to be possibly damaging based on the PolyPhen algorithm. Although SIFT predicts effects on protein function for p.Gln24Glu and p.Ala1394Thr, these predictions have a low confidence.

An in silico study for the possible splicing effects of the UVs, as determined by Netgene2, Splicesitefinder, Splice Site Predict and ESE-finder, revealed that none of the UVs were likely to cause splice defects. This analysis included donor and acceptor site changes as well as inactivation of exonic splicing enhancer sequences.

These in silico experiments suggest that the MLH3 UVs are likely to be benign, with the possible exception of p.Asn499Ser.

Transient Expression of MLH3 in HEK293T Cells

To evaluate the stability of the WT- or Mutant-YFP-MLH3 proteins, we transiently expressed Mutant-YFP-MLH3 in HEK293T cells. Notably, HEK293T cells are deficient for both MLH1 and MLH3 due to hypermethylation of the promoter regions of both genes (Cannavo et al., 2005). The wildtype MLH3 protein was stably expressed, even in the absence of MLH1 and the MLH3 expression levels of all UV-containing proteins were comparable with the expression level of the WT-YFP-MLH3 and that of one known missense polymorphism (p.Ser845Gly) (see Fig. 3A). The MLH3 protein variant with a frameshift mutation, p.Ans860IfsX13, was not detectable (see Fig. 3A). This was caused by shortening of the protein leading to a loss of the epitope recognized by the MLH3-antibody. The MLH3 (H-2) antibody is a mouse monoclonal antibody raised against amino acids 1228-1453 of human MLH3. To verify the presence of the truncated protein, we reprobed the blot with an anti-GFP antibody. A protein with the size expected for the truncated protein was detected (around 126 kDa), see Figure 3B. These results suggest normal expression of all UV-containing MLH3 proteins.

Subcellular Localization of MLH3

To evaluate whether the UV-containing MLH3 proteins were transported correctly into

Figure 2. Alignment of the human MLH3 protein with MLH3 proteins of different vertebrates. The alignment includes the (putative) MLH3 proteins of the following organism: *Homo sapiens, Rattus norvegicus, Mus musculus, Canis familiaris, Bos taurus, Gallus gallus, Xenopus* tropicalis, Pan troglodytes, and *Saccharomyces cerevisiae*. Only protein regions that contain the tested UVs are presented in this figure. The conservation is depicted in colors (blue represents badly conserved residues and red represents the best conserved residues). The multiple sequence alignment was performed using the M-COFFEE program. Although not depicted the amino acids in front of p.E624D and p.A1394T are also highly conserved. [Color figure can be viewed in the online issue, which is available at www.interscience.wiley.com.]

the nucleus, WT-YFP-MLH3 and Mutant-YFP-MLH3 were transfected into HEK293T cells or into HeLa cells. Figure 4 shows representative results of these experiments in HeLa cells (similar results were obtained in HEK293T cells, data not shown). In the HeLa and HEK293T cell lines, being MLH3-proficient and -deficient, respectively, all mutated and WT proteins were mainly localized in the nucleus. Some cytoplasmatic staining was seen, although this was independent of the presence of MLH1. These results suggest that the subcellular localization of the mutated proteins is normal. The subcellular localization for the MLH3 protein containing a truncating mutation clearly differs from the UV-containing mutations since, besides the nuclear staining, a strong cytoplasmatic staining was also observed.

Yeast Two-Hybrid Analysis

To determine whether MLH1 and UV-containing or wildtype MLH3 are able to form protein dimers in vivo, we performed a yeast two-hybrid screen. The screen, as shown in Figure 5, showed the MLH3 UVs analyzed, one known MLH3 missense polymorphism (p.Ser845Gly), and the MLH3 frameshift mutation identified (see Table 1). All mutated MLH3 proteins were able to interact with WT-MLH1 and this interaction was comparable with WT-MLH3-WT-MLH1 interaction and with that of the known missense polymorphism. The data suggest that the UV-containing MLH3 proteins can bind to WT-MLH1 in vivo.

The control experiments also showed colonies for the combination of the two empty vectors and the combination of pAS2 (empty vector) with

TABLE 2. In Silico Analyses of the Eight Tested MLH3 UVs

MLH3 UVs	Polarity change	Prediction by PolyPhen (score followed by prediction)	Prediction by SIFT (score followed by prediction)	Grantham scores			Prediction[a]	EMBL prediction	Splice defect prediction
				Distance [0–215]	Variation	Deviation			
p.Gln24Glu (p.Q24E)	P→AP	1.471; benign	0.05; affects protein function[b]	29	224.28	29.13	Class C0	Favored	No
p.Asn499Ser (p.N499S)	P→P	1.565; possibly damaging	0.70; tolerated	46	353.86	0.00	Class C0	Neutral	No
p.Glu624Gln (p.E624Q)	AP→P	1.184; benign	0.05; tolerated	29	353.86	0.00	Class C0	Favored	No
p.Ser817Gly (p.S817G)	P→NP	0.008; benign	0.48; tolerated	56	353.86	0.00	Class C0	Neutral	No
p.Gly981Ser (p.G981S)	NP→P	0.052; benign	1.00; tolerated	56	353.86	0.00	Class C0	Neutral	No
p.Asn1007Ser (p.N1007S)	P→P	0.185; benign	1.00; tolerated	46	353.86	0.00	Class C0	Neutral	No
p.Ala1394Thr (p.A1394T)	NP→P	1.413; benign	0.00; affects protein function[b]	58	353.86	0.00	Class C0	Neutral	No
p.Glu1451Lys (p.E1451K)	AP→P	1.267; benign	0.29; tolerated	56	353.86	0.00	Class C0	Neutral	No

P, polar amino acid (AA); NP, non-polar AA; AP, acidic charged polar AA; BP, basic charged polar AA.
[a]The classification is ordered from most likely to interfere with function (Class C65) to least likely to interfere with function (Class C0).
[b]There is low confidence in this prediction.

pACT2-MLH3. The observed colonies, however, were white whereas the colonies observed for the WT-MLH1 with WT- or MUTANT-MLH3 were all blue, as expected. We also observed interaction between the truncating MLH3 mutation (p.Ans860IfsX13) and WT-MLH1.

DISCUSSION

Previously, nine *MLH3* missense mutations and an *MLH3* frameshift mutation in patients suspected of having Lynch syndrome were detected (Wu et al., 2001). To clarify a possible role for eight of these *MLH3* UVs identified in suspected Lynch syndrome patients, we performed several biochemical tests.

Transfection of mutant and WT-MLH3 in an MLH3-deficient cell line, HEK293T, showed no difference in protein levels for the UVs tested. Our data also showed that the MLH3 protein is stable without a heterodimeric or other partner, corroborating previous findings (Cannavo et al., 2005). To repair mismatches in vivo, the MLH3 protein needs to be present in the nucleus. Recent localization experiments (Korhonen et al., 2007) suggested that endogenous MLH3 is mainly localized in the cytoplasm whereas MLH1 and PMS2 are localized in the nucleus in a human MMR-proficient cell line. It was also shown by Korhonen et al. (2007) that when MLH3 was transiently expressed in HCT116 (a human cell line deficient for MLH1 and PMS2), the MLH3 protein also localized in the cytoplasm. Only after cotransfection with MLH1, Korhonen et al. (2007) saw that MLH3 was partially transported into the nucleus. They conclude that nuclear localization of MLH3 is dependent on MLH1 and competitive with PMS2. Our data do not corroborate these findings as we observed with experiments performed in two independent labs that both WT and UV-containing MLH3 proteins were largely located in the nucleus and only partially in the cytoplasm, regardless of whether MLH3 was transfected alone or cotransfected with MLH1 and regardless of the cell line we used for transfection. When transfecting the vector expressing the truncated MLH3 protein (p.Asn860IfsX13) however, more cytoplasmatic staining can clearly be seen (see Fig. 4). The protein, however, is normally not expressed as the naturally occurring unprocessed mRNA containing such a frameshift mutation will be removed by the nonsense mediated RNA decay pathway.

Figure 3. A: Expression of UV-containing and wildtype MLH3 in HEK293T cells. This Western blot, using an MLH3 specific antibody, shows no differences in MLH3 expression on comparing cells transfected with WT-MLH3 and those transfected with UV-containing MLH3. B: Expression of MLH3 in HEK293T cells. This Western blot, using a GFP antibody shows in all but one lane the expected band of 190 kDa. In lane 7 (extracts from cells transfected with p.Asn860lfsX13-MLH3), a lower band is visible (126 kDa). Data shown are representative of three independent experiments. In this figure, an aspecific band of ∼150 kDa is visible in all lanes.


Figure 4. Subcellular localization of CFP-MLH1 and YFP-MLH3, WT-MLH3, the UV-containing MLH3s, and one truncating mutation containing MLH3 in HeLa cells. [Color figure can be viewed in the online issue, which is available at www.interscience.wiley.com.]

Figure 5. ß-gal assays (yeast two-hybrid assays) for WT-MLH3, the UV-containing MLH3s, and one truncating mutation containing MLH3. The first ten panels from left till right show the interaction between MLH3 (with the indicated UV) with WT-MLH1. Panel 11. MLH3 coupled to the GAL4 activation domain instead of the GAL4 DNA binding domain (as used in all other experiments) combined with empty vector, Panel 12. WT-MLH1 combined with empty vector, Panel 13. MLH1 (with a truncating mutation) combined with WT-MLH3, Panel 14. WT-MLH3 combined with an empty vector, Panel 15. Two empty vectors. [Color figure can be viewed in the online issue, which is available at www.interscience.wiley.com.]

To study whether the identified MLH3 UVs influence the interaction with MLH1 in vivo, we tested the MLH3 mutants in a yeast two-hybrid system. Yeast two-hybrid studies showed that all of the analyzed MLH3 mutants were able to interact with WT-MLH1 and that these interactions were comparable with a WT-MLH3-WT-MLH1 interaction. Surprisingly, we also observed interaction between the truncating MLH3 mutation (p.Asn860IfsX13) and WT-MLH1. A plausible explanation for this would be that a truncated MLH3 protein is produced, as shown in Figure 3B (see Results section, protein expression/stability studies). This truncated protein might still be able to interact with MLH1 to form a hetero-dimer with MLH1. Notably, the N-terminal MLH1 interaction domain was still present in the truncated form of MLH3, whereas the entire COOH-terminal MLH1 interaction domain was lacking (Fig. 1).

In conclusion, these biochemical assays do not show a change in the function of the mutated proteins we tested. Not finding a functional defect in these assays does, however, not preclude the *MLH3* UVs being involved in Lynch syndrome. The assays described above

investigate only specific biochemical aspects of MMR protein. It is conceivable that the UVs tested can cause a functional defect of the protein that was not detectable with the assays used in this study. We cannot therefore fully exclude these UVs from being pathogenic.

Besides data from biochemical assays, we also collected theoretical arguments that might help in determining the pathogenic nature of the MLH3 amino acid substitutions identified. We determined conservation in nine organisms and showed that seven of the amino acids that were mutated are highly conserved (Fig. 2). We also looked for polarity changes and saw again that several of the UVs give rise to substantial changes in polarity. However, when all of the data of the in silico analyses were analyzed we had to conclude that only based on Polyphen one of the eight UVs could be considered as possibly causative. The PolyPhen software combines structural, evolutionary and physicochemical properties. Notably, validation of the program showed a proper prediction in only 80% of known deleterious mutations, and thus false-positive or -negative findings can be expected (Sunyaev et al., 2000; Ng and Henikoff, 2002). However, the prediction results are in line with the biochemical assays described above, with the exception of p.Asn499Ser, which was predicted to be possibly damaging. Our in silico analysis on splicing showed that splicing abnormalities were not predicted for any of the UVs.

On the basis of the results from the biochemical assays and the theoretical prediction algorithms, we conclude that we have no convincing evidence that the MLH3 UVs tested are involved in the development of Lynch syndrome.

The above findings leave us with the question whether mutations in *MLH3* can contribute to the development of Lynch syndrome? Our data do not support any involvement of the *MLH3* UVs identified in Lynch syndrome. Our data are supporting a recent study on the MLH3 missense mutations p.Q24E, p.S817G, p.A1494T, and p.E1451K that were also biochemically evaluated in our study. Korhonen et al., (2008) show that these substitutions and three others (p.R647C, G933C, and W1276R) do not affect in vitro mismatch repair. Whether or not *MLH3* UVs involvement in Lynch syndrome can be concluded for the two reported *MLH3* frameshift mutations (Wu et al., 2001; Liu et al., 2003) remains unanswered. The fact that the tumors of these patients were MSI-low might be an argument against involvement in tumorigenesis. On the other hand, the finding of somatic mutations, knocking out the second allele in the tumor in three of the nine patients, argues in favor of their involvement (Wu et al., 2001). Importantly, these patients do not carry a germline mutation in one of the other important MMR genes (based on DNA sequence analysis and immunohistochemistry stainings) that could account for the second hit of *MLH3*. Furthermore, *PMS2* screening was performed for the carriers of MLH3 missense mutations p.Gln24Glu or p.Ala1494Thr and *PMS2* is not mutated in these patients. Finding MSI-L tumors in the *MLH3* frameshift mutation carriers should also be no surprise since it was shown that only a small but significant (20%) repair of both G/T mismatches and +1 insertion/deletion loop substrates was observed when MMR-deficient HEK293T nuclear protein extracts were supplemented with high amounts of MUTLγ. This suggests that MUTLγ might play a backup role in human MMR (Cannavo et al., 2005). In addition, it might be that MLH3 is more involved in tetranucleotide instability as shown in Table 1. In the article of Wu et al., (2001) it has already been shown that the use of five most informative markers (3 dinucleotide and 2 tetranucleotide markers) show that 77% of the tumors of *MLH*3 missense mutation carriers show an MSI-H phenotype.

A low activity is also reflected in the presence of low amounts of endogenous MLH3 protein in human cell lines. Semiquantitative Western analysis of HeLa cells revealed endogenous MLH3 levels 60 times less abundant than PMS2 and 6 times less abundant than PMS1 (Cannavo et al., 2005). Finally, as previously shown by others (Cannavo et al., 2005), and now confirmed in this study, MLH3 is stable in the absence of MLH1. As the other proteins that are facultative partners of MMR components (PMS2, MSH6), are unstable in the absence of their partner, MLH3 seems to behave differently compared with the other MMR proteins which could be seen as an argument against involvement in MMR.

In conclusion, we analyzed the functional significance of eight *MLH3* UVs by in silico analyses and biochemical assays. Our assays show that the MLH3 UVs are likely to be as functional as the wildtype MLH3 protein, suggesting that *MLH3* is not a major player in Lynch syndrome. However, we cannot fully exclude a role for MLH3 as a modifier in tumorigenesis.

ACKNOWLEDGMENTS

REFERENCES

Betts MJ, Russell RB. 2003. Amino acid properties and consequences of subsitutions. In: Barnes MR, Gray IC, editors. Bioinformatics for Geneticists. West Sussex (UK): John Wiley & Sons, pp. 289–316.

Bradford MM. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248–254.

Cannavo E, Marra G, Sabates-Bellver J, Menigatti M, Lipkin SM, Fischer F, Cejka P, Jiricny J. 2005. Expression of the MutL homologue hMLH3 in human cells and its role in DNA mismatch repair. Cancer Res 65:10759–10766.

Chen PC, Dudley S, Hagen W, Dizon D, Paxton L, Reichow D, Yoon SR, Yang K, Arnheim N, Liskay RM, Lipkin SM. 2005. Contributions by MutL homologues Mlh3 and Pms2 to DNA mismatch repair and tumor suppression in the mouse. Cancer Res 65:8662–8670.

Chen PC, Kuraguchi M, Velasquez J, Wang Y, Yang K, Edwards R, Gillen D, Edelmann W, Kucherlapati R, Lipkin SM. 2008. Novel roles for MLH3 deficiency and TLE6-like amplification in DNA mismatch repair-deficient gastrointestinal tumorigenesis and progression. PLoS Genet 4:e1000092.

Chung DC, Rustgi AK. 2003. The hereditary nonpolyposis colorectal cancer syndrome: genetics and clinical implications. Ann Intern Med 138:560–570.

Flores-Rozas H, Kolodner RD. 1998. The *Saccaromyces cerevisiae MLH3* gene functions in MSH3-dependent suppression of frameshift mutations. Proc Natl Acad Sci USA 95:12404–12409.

Grantham R. 1974. Amino acid difference formula to help explain protein evolution. Science 185:862–864.

Harfe BD, Minesinger BK, Jinks-Robertson S. 2000. Discrete in vivo roles for the MutL homologs Mlh2p and Mlh3p in the removal of frameshift intermediates in budding yeast. Curr Biol 10:145–148.

Jiricny J. 2006. The multifaceted mismatch-repair system. Nat Rev Mol Cell Biol 7:335–346.

Kim JC, Roh SA, Yoon YS, Kim HC, Park IJ. 2007. MLH3 and EXO1 alterations in familial colorectal cancer patients not fulfilling Amsterdam criteria. Cancer Genet Cytogenet 176:172–174.

Kondo E, Horii A, Fukushige, S. 2001. The interacting domains of three MutL heterodimers in man: hMLH1 interacts with 36 homologous amino acid residues within hMLH3, hPMS1 and hPMS2. Nucl Acid Res 29:1695–1702.

Korhonen MK, Raevaara TE, Lohi H, Nystrom M. 2007. Conditional nuclear localization of hMLH3 suggests a minor activity in mismatch repair and supports its role as a low-risk gene in HNPCC. Oncol Rep 17:351–354.

Korhonen MK, Vuorenmaa E, Nyström M. 2008. The first functional study of *MLH3* mutations found in cancer patients. Genes Chromosomes Cancer 47:803–809.

Liberti SE, Rasmussen LJ. 2004. Is hEXO1 a cancer predisposing gene? Mol Cancer Res 2:427–432.

Lipkin SM, Wang V, Jacoby R, Banerjee-Basu S, Baxevanis AD, Lynch HT, Elliott RM, Collins FS. 2000. MLH3: A DNA mismatch repair gene associated with mammalian microsatellite instability. Nat Genet 24:27–35.

Liu HX, Zhou XL, Liu T, Werelius B, Lindmark G, Dahl N, Lindblom A. 2003. The role of hMLH3 in familial colorectal cancer. Cancer Res 63:1894–1899.

Liu HX, Li Y, Jiang XD, Yin HN, Zhang L, Wang Y, Yang J. 2006. Mutation screening of mismatch repair gene Mlh3 in familial esophageal cancer. World J Gastroenterol 12:5281–5286.

Mathe E, Olivier M, Kato S, Ishioka C, Hainaut P, Tavtigian SV. 2006. Computational approaches for predicting the biological effect of p53 missense mutations: A comparison of three sequence analysis based methods. Nucleic Acids Res 34:1317–25.

Moretti S, Armougom F, Wallace IM, Higgins DG, Jongeneel CV, Notredame C. 2007. The M-Coffee web server: a meta-method for computing multiple sequence alignments by combining alternative alignment methods. Nucleic Acids Res 35 (Web Server issue):W645–W648.

Ng PC, Henikoff S. 2002. Accounting for human polymorphisms predicted to affect protein function. Genome Res 12:436–446.

Peltomaki P, Vasen H. 2004. Mutations associated with HNPCC predisposition—Update of ICG-HNPCC/INSiGHT mutation database. Dis Markers 20:269–276.

Perucho M. 1999. Correspondence re: C.R. Boland et al., A National Cancer Institute workshop on microsatellite instability for cancer detection and familial predisposition: Development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 58:5248–5257, 1998. Cancer Res 59:249–256.

Rasmussen LJ, Rasmussen M, Lee B, Rasmussen AK, Wilson DM, III, Nielsen FC, Bisgaard HC. 2000. Identification of factors interacting with hMSH2 in the fetal liver utilizing the yeast two-hybrid system. In vivo interaction through the C-terminal domains of hEXO1 and hMSH2 and comparative expression analysis. Mutat Res 460:41–52.

Sunyaev SR, Lathe WC, III, Ramensky VE, Bork P. 2000. SNP frequencies in human genes an excess of rare alleles and differing modes of selection. Trends Genet 16:335–337.

Tavtigian SV, Deffenbaugh AM, Yin L, Judkins T, Scholl T, Samollow PB, de Silva D, Zharkikh A, Thomas A. 2005. Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral. J Med Genet 43:295–305.

Taylor NP, Powell MA, Gibb RK, Rader JS, Huettner PC, Thibodeau SN, Mutch DG, Goodfellow PJ. 2006. MLH3 mutation in endometrial cancer. Cancer Res 66:7502–7508.

Tishkoff DX, Boerger AL, Bertrand P, Filosi N, Gaida GM, Kane MF, Kolodner RD. 1997. Identification and characterization of *Saccharomyces cerevisiae* EXO1, a gene encoding an exonuclease that interacts with MSH2. Proc Natl Acad Sci USA 94:7487–7492.

Tran PT, Simon JA, Liskay RM. 2001. Interactions of Exo1p with components of MutLalpha in *Saccharomyces cerevisiae*. Proc Natl Acad Sci USA 98:9760–9765.

Wu Y, Berends MJ, Sijmons RH, Mensink RG, Verlind E, Kooi KA, van der ST, Kempinga C, van der Zee AG, Hollema H, Buys CH, Kleibeuker JH, Hofstra RM. 2001. A role for MLH3 in hereditary nonpolyposis colorectal cancer. Nat Genet 29:137–138.